Literature DB >> 16966961

Use of beryllium lymphocyte proliferation testing for screening of asymptomatic individuals: an evidence-based assessment.

Jonathan Borak1, Steven H Woolf, Cheryl A Fields.   

Abstract

OBJECTIVE: We reviewed published data describing use of beryllium lymphocyte proliferation testing (BeLPT) to determine the appropriateness of BeLPT for screening asymptomatic individuals.
METHODS: Published studies were identified by computerized literature searches and hand searches of relevant bibliographies and cited references. Critical assessment of evidence focused on five elements essential to judging effectiveness of preventive services: 1) burden of suffering, 2) accuracy and reliability of screening tests, 3) effectiveness of early detection, 4) harms of screening, and 5) benefits outweighing harms.
RESULTS: Important gaps and deficiencies in the evidence were found. The prevalence of beryllium sensitization and chronic beryllium disease in asymptomatic individuals are unknown. The accuracy and reliability of BeLPT are uncertain. Marked intra- and interlaboratory variability has been reported. The clinical benefits of early intervention have not been confirmed or quantified in asymptomatic individuals.
CONCLUSIONS: There is currently insufficient scientific evidence to support the use of BeLPT for routine screening of asymptomatic individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966961     DOI: 10.1097/01.jom.0000232548.03207.9f

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  5 in total

1.  Consenting to uncertainty: challenges for informed consent to disease screening--a case study.

Authors:  Mark Greene; Suzanne M Smith
Journal:  Theor Med Bioeth       Date:  2008-12-05

2.  Beryllium history and public policy.

Authors:  Marc Kolanz
Journal:  Public Health Rep       Date:  2008 Jul-Aug       Impact factor: 2.792

3.  Considerations on occupational medical surveillance in employees handling nanoparticles.

Authors:  Michael Nasterlack; Andreas Zober; Christoph Oberlinner
Journal:  Int Arch Occup Environ Health       Date:  2007-09-12       Impact factor: 3.015

4.  Progression from beryllium exposure to chronic beryllium disease: an analytic model.

Authors:  Philip Harber; Siddharth Bansal; John Balmes
Journal:  Environ Health Perspect       Date:  2009-02-27       Impact factor: 9.031

5.  Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease.

Authors:  Margaret M Mroz; Lisa A Maier; Matthew Strand; Lori Silviera; Lee S Newman
Journal:  Am J Ind Med       Date:  2009-10       Impact factor: 2.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.